Inmune Bio, Inc. (INMB) intrinsic value & 10-year financials
Inmune Bio, Inc. (INMB) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 35.6% a year to $50.0K, with an average return on invested capital of -137.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.57
- Market cap
- $38.9M
- Revenue (FY2025)
- $50.0K
- Revenue growth (10-yr CAGR)
- 35.6%
- ROIC (10-yr avg)
- -137.4%
- Free cash flow (FY2025)
- -$23.6M
INMB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $50.0K | -$45.9M | -$1.86 | -$23.6M | -94766.0% | -358.8% |
| FY2024 | $14.0K | -$42.1M | -$2.11 | — | -304535.7% | -220.2% |
| FY2023 | $155.0K | -$30.0M | -$1.67 | — | -19187.7% | -171.6% |
| FY2022 | $374.0K | -$27.3M | -$1.52 | — | -6938.8% | -124.4% |
| FY2021 | $181.0K | -$30.3M | -$1.88 | — | -16106.6% | -161.3% |
| FY2020 | $10.9K | -$12.1M | — | — | -112016.1% | -71.8% |
| FY2019 | — | -$7.7M | — | — | — | -45.8% |
| FY2018 | $0 | -$12.4M | — | — | — | -71.8% |
| FY2017 | $0 | -$831.5K | — | — | — | -10.9% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Inmune Bio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Inmune Bio, Inc. has historically struggled to out-earn its cost of capital, averaging just -35.9% ROIC.
Inmune Bio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Inmune Bio, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-61.78 per share.